Cargando…
Malignant Sinonasal Tumors: Update on Histological and Clinical Management
Tumors of nasal cavity and paranasal sinuses (TuNSs) are rare and heterogeneous malignancies, presenting different histological features and clinical behavior. We reviewed the literature about etiology, biology, and clinical features of TuNSs to define pathologic features and possible treatment stra...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293118/ https://www.ncbi.nlm.nih.gov/pubmed/34287240 http://dx.doi.org/10.3390/curroncol28040222 |
_version_ | 1783724961395900416 |
---|---|
author | Bracigliano, Alessandra Tatangelo, Fabiana Perri, Francesco Di Lorenzo, Giuseppe Tafuto, Roberto Ottaiano, Alessandro Clemente, Ottavia Barretta, Maria Luisa Losito, Nunzia Simona Santorsola, Mariachiara Tafuto, Salvatore |
author_facet | Bracigliano, Alessandra Tatangelo, Fabiana Perri, Francesco Di Lorenzo, Giuseppe Tafuto, Roberto Ottaiano, Alessandro Clemente, Ottavia Barretta, Maria Luisa Losito, Nunzia Simona Santorsola, Mariachiara Tafuto, Salvatore |
author_sort | Bracigliano, Alessandra |
collection | PubMed |
description | Tumors of nasal cavity and paranasal sinuses (TuNSs) are rare and heterogeneous malignancies, presenting different histological features and clinical behavior. We reviewed the literature about etiology, biology, and clinical features of TuNSs to define pathologic features and possible treatment strategies. From a diagnostic point of view, it is mandatory to have high expertise and perform an immunohistochemical assessment to distinguish between different histotypes. Due to the extreme rarity of these neoplasms, there are no standard and evidence-based therapeutic strategies, lacking prospective and large clinical trials. In fact, most studies are retrospective analyses. Surgery represents the mainstay of treatment of TuNSs for small and localized tumors allowing complete tumor removal. Locally advanced lesions require more demolitive surgery that should be always followed by adjuvant radio- or chemo-radiotherapy. Recurrent/metastatic disease requires palliative chemo- and/or radiotherapy. Many studies emphasize the role of specific genes mutations in the development of TuNSs like mutations in the exons 4–9 of the TP53 gene, in the exon 9 of the PIK3CA gene and in the promoter of the TERT gene. In the near future, this genetic assessment will have new therapeutic implications. Future improvements in the understanding of the etiology, biology, and clinical features of TuNSs are warranted to improve their management. |
format | Online Article Text |
id | pubmed-8293118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82931182021-07-22 Malignant Sinonasal Tumors: Update on Histological and Clinical Management Bracigliano, Alessandra Tatangelo, Fabiana Perri, Francesco Di Lorenzo, Giuseppe Tafuto, Roberto Ottaiano, Alessandro Clemente, Ottavia Barretta, Maria Luisa Losito, Nunzia Simona Santorsola, Mariachiara Tafuto, Salvatore Curr Oncol Review Tumors of nasal cavity and paranasal sinuses (TuNSs) are rare and heterogeneous malignancies, presenting different histological features and clinical behavior. We reviewed the literature about etiology, biology, and clinical features of TuNSs to define pathologic features and possible treatment strategies. From a diagnostic point of view, it is mandatory to have high expertise and perform an immunohistochemical assessment to distinguish between different histotypes. Due to the extreme rarity of these neoplasms, there are no standard and evidence-based therapeutic strategies, lacking prospective and large clinical trials. In fact, most studies are retrospective analyses. Surgery represents the mainstay of treatment of TuNSs for small and localized tumors allowing complete tumor removal. Locally advanced lesions require more demolitive surgery that should be always followed by adjuvant radio- or chemo-radiotherapy. Recurrent/metastatic disease requires palliative chemo- and/or radiotherapy. Many studies emphasize the role of specific genes mutations in the development of TuNSs like mutations in the exons 4–9 of the TP53 gene, in the exon 9 of the PIK3CA gene and in the promoter of the TERT gene. In the near future, this genetic assessment will have new therapeutic implications. Future improvements in the understanding of the etiology, biology, and clinical features of TuNSs are warranted to improve their management. MDPI 2021-07-01 /pmc/articles/PMC8293118/ /pubmed/34287240 http://dx.doi.org/10.3390/curroncol28040222 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bracigliano, Alessandra Tatangelo, Fabiana Perri, Francesco Di Lorenzo, Giuseppe Tafuto, Roberto Ottaiano, Alessandro Clemente, Ottavia Barretta, Maria Luisa Losito, Nunzia Simona Santorsola, Mariachiara Tafuto, Salvatore Malignant Sinonasal Tumors: Update on Histological and Clinical Management |
title | Malignant Sinonasal Tumors: Update on Histological and Clinical Management |
title_full | Malignant Sinonasal Tumors: Update on Histological and Clinical Management |
title_fullStr | Malignant Sinonasal Tumors: Update on Histological and Clinical Management |
title_full_unstemmed | Malignant Sinonasal Tumors: Update on Histological and Clinical Management |
title_short | Malignant Sinonasal Tumors: Update on Histological and Clinical Management |
title_sort | malignant sinonasal tumors: update on histological and clinical management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293118/ https://www.ncbi.nlm.nih.gov/pubmed/34287240 http://dx.doi.org/10.3390/curroncol28040222 |
work_keys_str_mv | AT braciglianoalessandra malignantsinonasaltumorsupdateonhistologicalandclinicalmanagement AT tatangelofabiana malignantsinonasaltumorsupdateonhistologicalandclinicalmanagement AT perrifrancesco malignantsinonasaltumorsupdateonhistologicalandclinicalmanagement AT dilorenzogiuseppe malignantsinonasaltumorsupdateonhistologicalandclinicalmanagement AT tafutoroberto malignantsinonasaltumorsupdateonhistologicalandclinicalmanagement AT ottaianoalessandro malignantsinonasaltumorsupdateonhistologicalandclinicalmanagement AT clementeottavia malignantsinonasaltumorsupdateonhistologicalandclinicalmanagement AT barrettamarialuisa malignantsinonasaltumorsupdateonhistologicalandclinicalmanagement AT lositonunziasimona malignantsinonasaltumorsupdateonhistologicalandclinicalmanagement AT santorsolamariachiara malignantsinonasaltumorsupdateonhistologicalandclinicalmanagement AT tafutosalvatore malignantsinonasaltumorsupdateonhistologicalandclinicalmanagement |